Skip to main content

Gail A. Spiridigliozzi

Professor in Psychiatry and Behavioral Sciences
Psychiatry, Child & Family Mental Health & Community Psychiatry
Box 2906 Med Ctr, Durham, NC 27710
Exchange on Erwin, 2608 Erwin Road, Suite 300, Durham, NC 27705

Overview


Cholinergic therapy in children and adolescents with Down syndrome; premutation carriers of fragile X syndrome; cognitive development of children with infantile-onset Pompe disease who are being treated with enzyme replacement therapy.

Current Appointments & Affiliations


Professor in Psychiatry and Behavioral Sciences · 2022 - Present Psychiatry, Child & Family Mental Health & Community Psychiatry, Psychiatry & Behavioral Sciences
Professor in Pediatrics · 2022 - Present Pediatrics, Clinical Science Departments

Recent Publications


Infantile-onset Pompe disease entering adulthood: Insights from 2 decades of enzyme replacement therapy experience.

Journal Article Genet Med · December 2025 PURPOSE: This study details the long-term clinical outcomes in adult participants with CRIM-positive infantile-onset Pompe disease treated with enzyme replacement therapy (ERT), initially reported in 2012 (n = 11). METHODS: Medical records were reviewed fo ... Full text Link to item Cite

The Detection of Down Syndrome Arthritis in Clinical Practice: A Multicenter, International Pilot and Feasibility Study of a Down Syndrome-Specific Musculoskeletal Screening Tool.

Journal Article Am J Med Genet A · November 6, 2025 Down syndrome (DS) is associated with an increased risk for an inflammatory arthritis termed Down syndrome-associated arthritis (DA). Clinical awareness of DA may prevent morbidity, but there is currently no consensus approach to screen for DA. A DS muscul ... Full text Link to item Cite

Navigating the Emotional and Practical Challenges of Newborn Screening for Late-Onset Pompe Disease: Insights From Parental Perspectives.

Journal Article Pediatr Neurol · November 2025 Pompe disease (PD), an autosomal recessive lysosomal disorder, results in glycogen accumulation in muscle cells, leading to progressive muscle weakness and respiratory insufficiency. Newborn screening (NBS) has improved outcomes for infantile-onset PD by e ... Full text Link to item Cite
View All Publications

Recent Grants


Understanding cognitive and neurological pathologies in infantile Pompe disease CNS

Clinical TrialInvestigator · Awarded by Genzyme Corporation · 2022 - 2030

Understanding cognitive and neurological pathologies in infantile Pompe disease

Clinical TrialInvestigator · Awarded by Genzyme Corporation · 2016 - 2018

What about adolescence? Living with genetic risk

ResearchCo Investigator · Awarded by National Institutes of Health · 2004 - 2007

View All Grants

Education, Training & Certifications


University of Kansas · 1988 Ph.D.